



























































































































































































































































































































































































































































































































































































































CD (5, 19 etc)      Cluster of differentiation 
CD40L        CD40 ligand 
CDS          Coding domain sequence 
CFSE          Carboxyfluorescein succinimidyl ester 
ChIP          Chromatin immunoprecipitation 
CLL  Chronic lymphocytic leukaemia 





DMSO        Dimethyl sulfoxide 
DNA  Deoxyribonucleic acid 
ECL  Enhanced chemiluminescence 











FITC          Fluorescein isothiocyanate 























LiCL          Lithium chloride   









MOI          Multiplicity of infection 













PCR          Polymerase chain reaction 
PE          Phycoerythrin 





PRDM1        PR domain zinc finger protein 1 
pre‐BCR        Pre B cell receptor 
PVDF  Polyvinylidene fluoride 
qPCR         Quantitative PCR 
RISC  RNA‐induced silencing complex 
RNA          Ribonucleic acid 
RNAi  RNA interference 





shRNA        Short hairpin RNA 











TRIS          Tris(hydroxymethyl)aminomethane 
Tu  Viral titres 




















































Figure 1.1 B cell maturation
B cell development in the bone marrow features sequential heavy and then light chain rearrangement and maturation of the B cell receptor
(BCR). The heavy chain immunoglobulin locus is rearranged in pro‐B cells. When the heavy chain µ protein is expressed in the cytoplasm, it is
paired with surrogate light chains to form the pre‐BCR. Autonomous signalling via the pre‐BCR leads to a short‐lived clonal expansion of
these large pre‐B cells. The pre‐BCR is then downregulated and the cells exit the cell cycle and enter a resting phase as small pre‐B cells. The
immunoglobulin light chain locus is rearranged. Rearranged light chains combine with heavy chains to form the mature BCR which is



























































Figure 1.2 B cell differentiation through the germinal centre
After encountering an antigen, naïve B cells are activated by their interactions in the T cell rich zone of the lymph node, and the germinal centre reaction is initiated. B cells
proliferate rapidly as centroblasts in the dark zone of the lymph node. These cells undergo somatic hypermutation (SHM) to diversify the heavy and light chain regions of their
surface immunoglobulins. In the light zone, rapid proliferation slows down and some of these centrocytes undergo class switch recombination (CSR) of their immunoglobulin
isotype. Interactions with T cells and follicular dendritic cells select the cells with highest antigen affinity which then differentiate to plasma cells or memory B cells. Figure modified





























































Table 1.1 Discovery of IRF4
IRF4 was first identified in a number of different guises, binding to murine kappa and lambda light chains in a
heterodimer with PU.1, and to the human interleukin‐5 gene in a T cell leukaemia line. Its expression was











































Figure 1.3 IRF4 protein structure
IRF4 is a 450 amino acid protein comprising an N terminal DNA binding domain and a C terminal interferon activation domain (IAD), separated by a flexible linker.
(Pongubala et al., 1992; Eisenbeis et al., 1995; Grossman et al., 1996; Brass et al., 1999; Remesh et al., 2015) The IAD is critical for mediating protein‐protein
interactions. The DNA binding domain shares significant homology with other members of the IRF family courtesy of a tryptophan‐repeat sequence (five
tryptophans repeated at 10‐18 amino acid intervals). (Nguyen et al., 1997) At this region, IRF4 is able to bind to the interferon stimulated response element (ISRE)
of target genes. (Nguyen et al., 1997; Mamane et al., 1999) An autoregulatory (AR) domain at the C terminal of the protein contains an autoinhibitory region which
physically interacts with the DNA binding domain and maintains the protein in an inhibited state. (Brass et al., 1996) Interaction of the IAD with a binding partner
such as PU.1 via the PEST (rich in proline (P), glutamic acid (E), serine (S), threonine (T)) region of PU.1 relieves this autoinhibition and allows IRF4 to bind its target
sequence. (Pongubala et al., 1993; Brass et al., 1996) In this way, IRF4 can bind to target composite Ets/ IRF consensus element (EICE) sequences in target genes.


























































































































Figure 1.4 IRF4 is essential to the germinal centre reaction
IRF4 is essential to the initiation of the germinal centre reaction and mice who are IRF4 ‐/‐ lack germinal centres. IRF4 is not expressed in the germinal centre dark zone
but coordinates essential processes in the light zone: class switch recombination (CSR); selection of cells with high affinity for antigen; and plasmacytic differentiation.










































































































Figure 1.5 Graded expression of IRF4 coordinates class switch recombination (CSR) and plasmacytic differentiation through a model of ‘kinetic
control’
Low IRF4 expression in mouse studies leads to induction of Aicda and AID expression and thus class switch recombination (CSR) in the light zone
of the germinal centre. High IRF4 expression in contrast leads to downregulation of Aicda/AID expression and induces Prdm1 and BLMP1
expression. High IRF4 expression also represses expression of BCL6, a critical regulator of the germinal centre reaction. Thus, high IRF4 expression
drives the plasma cell differentiation programme and exit from the germinal centre. The level of IRF4 expression is determined by the strength of
signalling via the B cell receptor (BCR). Germinal centre B cells expressing high affinity antibodies thus engage their BCR more readily and receive
strong BCR signalling. These cells therefore express high levels of IRF4 and are driven towards the plasma cell differentiation programme and exit
from the germinal centre. B cells with low affinity antibodies receive weaker BCR signalling and thus have lower IRF4 expression. These cells are
therefore retained in the germinal centre to undergo further rounds of CSR to generate antibodies of higher affinity. (Sciammas et al., 2006;

















































































































































Table 1.2 Matute scoring system for CLL diagnosis; Binet and Rai
scoring systems for staging disease
A.Matutes scoring system, adapted from Matutes et al, 1994.
B. Binet staging system, adapted from Binet et al, 1981.
*No anaemia or thrombocytopaenia, defined as haemoglobin
≥10g/dL, platelets ≥100x109/l
$Nodal areas defined as: cervical, axillary and inguinal lymphoid,
hepatomegaly and splenomegaly
ᵻAnaemia or thrombocytopaenia, defined as haemoglobin <10g/dL,
platelets <100x109/l
C. Rai staging system, adaptd from Rai et al, 1975.









































































































































Table 1.3 Incidence of common acquired cytogenetic abnormalities in CLL and their impact on survival
FISH analysis of 325 patients with CLL revealed a genetic abnormality in 82% of the cases. Cox’s proportional hazards
regression model was used to construct a hierarchical model of genetic abnormalities, in which each case was assigned
to one subgroup only. Patients with del (13q) as their sole genetic abnormality had the longest median overall survival
time. In contrast, patients with del (17p) had a significantly shorter median survival of under 3 years. Adapted from



















































































































































































































































































































































































































































































































































SNP Chromosome Gene OR Reference
rs872071 6p25.3 IRF4 1.54
(Di Bernardo et al., 
2008)
rs735665 11q24.1 GRAMD1B 1.45
rs7176508 15q21.3 1.4
rs13397985 2q37.1 SP140, SP110 1.4
rs17483466 2q13 ACOXL, BCL2L11 1.4




rs757978 2q37.3 FIR 1.4
rs305061 16q24.1 IRF8 1.2
rs7169431 15q21.3 RFX7, NEDD4 1.4
rs783540 15q25.2 CPEB1 1.2 (Crowther‐Swanepoelet al., 2011)
rs674313 (Slager et al., 2011)
rs210142 6p21.33 BAk1 1.4 (Slager et al., 2012)
rs1044873 16q24.1 IRF8 (Slager et al., 2013)
rs4406737 10q23 ACTA2, FAS 1.3
(Berndt et al., 2013)
rs4987855 18q21 BCL2 1.5
rs7944004 11p15.5 C11orf21 1.2
rs898518 4q25 LEF1 1.2
rs3769825 2q33 CASP10, CASP8 1.2
rs1679013 9p21 CDKN2B‐AS1 1.2
rs4368253 18q21 PMAIP1 1.2
rs8024033 15q15 BMF 1.2
rs3770745 2p22 QPCT 1.2




rs2236256 6q25.2 IPCEF1 1.2
rs17246404 7q31.33 POT1 1.2
rs10069690 5p15.33 TERT
rs2511714 8q22.33
rs10735079 12q24.13 OAS (Sava et al., 2015)
Table 1.4 Risk alleles for CLL identified in genome wide association studies
(GWAS)
Thirty‐one common risk alleles for CLL have been identified in GWAS studies, all
with a minor allele frequency (MAF) of greater than 0.1. OR indicates odds ratio














































Figure 1.6 rs872071 risk allele in IRF4
rs872071, a single nucleotide polymorphism (SNP) in IRF4, is a low penetrance,
high risk allele for the development of CLL. (Di Bernardo et al., 2008)
A. Furthermore, in an analysis of 840 CLL patients of the Newcastle CLL
consortium, both heterozygote and homozygote carriers of the risk allele (A>G)
had significantly worse treatment free survival than non‐carriers (p=0.015). (Allan
et al., 2010)
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MEC‐1 and MEC‐2 0.5‐2.0 IMDM20% / IMDM 10%
CD40L/NTL fibroblast 
cells 30‐80% confluence RF10%
Table 2.1 Cell lines
TK6 cell line and CD40L‐expressing and parental non‐expressor (NTL) fibroblast cell lines were
maintained in RF10% media (comprising RPMI 1640 medium, supplemented with 10% (v/v) FBS
and 50ug/ml penicillin/streptomycin). SU‐DHL‐6 was maintained as a suspension cell culture in
RF20% media (RPMI 1640 medium, supplemented with 20% (v/v) FBS and 50ug/ml
penicillin/streptomycin). MEC‐1 and MEC‐2 cells were cultured in IMDM 20% (IMDM,
supplemented with 20% (v/v) FBS and 50ug/ml penicillin/ streptomycin) for one week after





























































































Fludarabine 365.21 DMSO 50 ‐20ᵒC
Ibrutinib 440.5 DMSO 50 ‐80ᵒC
Bendamustine 394.72 Sterile water 50 ‐20ᵒC
Table 2.2 Preparation of cytotoxic agents for growth inhibition assays


































































type Isotype Supplier Cat No. Dilution
Primary antibodies
IRF4 52 Polyclonal Goat IgG Santa Cruz sc‐6059 1: 30 000
PU.1 37 Polyclonal Rabbit IgG Santa Cruz sc‐352 1:10 000
ICSBP/ IRF8 52 Polyclonal Goat IgG Santa Cruz sc‐6058 1:10 000















































siRNA Target sequence Sense strand Antisense strand Supplier Cat No.
Hs_IRF4_1 5’‐CCCGACGGGCTCTATGCGAAA‐3’ 5’‐CGACGGGCUCUAUGCGAAATT‐3’ 5’‐UUUCGCAUAGAGCCCGUCGGG‐3’ Qiagen SI00038150



















































































































































































































































Protein target Species and isotype Supplier Cat no.
Test ChIP antibodies
IRF4 Goat IgG Santa Cruz sc‐6059
Histone 3 trimethyl lysine 9 (H3K9me3) Rabbit IgG Abcam ab8898
Histone 3 trimethyl lysine 4 (H3K4me3) Rabbit IgG Diagenode pAb‐003‐010
Histone 3 trimethyl lysine 9 (H3K9me3) Rabbit IgG Diagenode pAb‐056‐050
Control ChIP antibodies
‐ Goat IgG Santa Cruz sc‐2028








































































































































































































































































































Protein Fluorochrome Antibody species Clone Isotype Cat No.
CD38 PE Mouse Anti‐Human HIT2 Mouse IgG1, κ 555460
CD154 PE Mouse Anti‐Human TRAP1 Mouse IgG1, κ 555700
CD5 APC Mouse Anti‐Human UCHT2 Mouse IgG1, κ 555355
CD19 PerCP Mouse Anti‐Human 4G7 Mouse IgG1, κ 345778
CFSE CFSE ‐ ‐ ‐ 34554 Invitrogen
Isotype 


































































Figure 2.1 Optimising CD38 antibody concentration for use in primary CLL lymphocytes
In order to select the optimal CD38 antibody concentration for use in the investigation of CD38 surface expression in primary CLL lymphocytes, the antibody was titrated at 6 different
concentrations (ranging from 0.008µg/µl to 0.25µg/µl). A species‐matched isotype control antibody was used at equivalent concentrations. Primary CLL lymphocytes were isolated from two
patients, one of whom was known to be CD38 positive (X), and one of whom was CD38 negative (Y). Geometric mean fluorescence intensity and CD38% positivity were analysed.
A and B. In patient Y, binding by both antibodies showed a modest increase in geometric mean fluorescence intensity as antibody concentration increased. However, this increased binding occurred
in parallel for the two antibodies and there was no evidence of excessive non‐specific binding with the CD38 antibody compared to the isotype control antibody, even at the highest concentrations.
C and D. In patient X, low concentrations of the CD38 antibody (up to approximately 0.1µg/µl) were insufficient to demonstrate CD38 positivity. In addition, a steep ‘shoulder’ was observed in (E) in
the relative mean fluorescence (RMF) of CD38 positivity in cells from patient X (CD38 positive), using antibody concentrations up to approximately 0.2µg/µl. This steep increase in RMF could lead to











































































































































Figure 2.2 Using flow cytometry to assess CD38 expression in primary CLL lymphocytes
A. After gating cells according to forward and side scatter, CLL lymphocytes were selected by gating for a CD5
positive and CD19 positive cell population.
B. This gated population was then inspected in a histogram plot to determine CD38 expression. Instrument
settings were adjusted to position the gated population, unlabelled at first for CD38 or isotype matched
control antibody, into the first decade of the histogram plot. Nearly 100% of events (cells) are captured
within an M1 marker, which allows the determination of the geometric mean and median fluorescence
intensity of the cell population.
C. Cells were labelled with isotype control antibody. An M2 marker bar was positioned to capture 5% of this
isotype‐labelled cell population. This M2 marker bar was then left untouched for analysis of percentage CD38
antibody‐labelled cells.
D. CD38 antibody‐labelled cells were then analysed. 42% of the cells fall within the M2 marker bar and thus
these cells are considered 42% CD38 positive. Geometric mean and median fluorescence data indicating the
intensity of the cell population fluorescence can also be obtained from the histogram plot. Relative mean
fluorescence was determined by the relative geometric mean fluorescence of the CD38 antibody‐labelled

















































































































































































5’ AGGTCAAGGGAAATTACTG                                                                    CAGAAAATTGAAACTGGAT                  AACAAAAGCGAAAATGACA                                  CA 
CAGGAACAGAAAACCAAGCAT                          CTGAGGCAAGGGGTTGGGGGTGGGAAGGGAAACAGAGAAAAGGCAAGTGAAACAGAAGGGGAGGTGCAGTTTCAGAACCC         






The  forward  strand  sequence  is displayed  and base positions  are  indicated underneath  the  sequence. Black  text  indicates  the 
upstream flanking sequence; green text indicates 5’UTR; red text indicates coding sequence. The 5’ base position of each putative 


































































Table 3.1 TK6 expresses surface CD38
Flow cytometry of TK6 cell line reveals a CD10 negative B cell line
which weakly expresses CD79b and is negative for IgG. It expresses









Figure 3.2 TK6 cell line expresses IRF4 protein
Whole cell extracts were prepared from B‐lymphoblastoid cell line,
TK6, and from the myeloid leukaemia cell lines, HL‐60 and NB4.
After quantifying the protein concentration obtained from each
cell line using Pierce BCA assay, equal quantities of protein per
sample were loaded for gel electrophoresis by SDS‐PAGE. The
proteins were transferred by electrophoresis to PVDF membrane
which was blocked in 5% blocking buffer and then probed with
primary antibody directed against IRF4. The membrane was then
probed with a species‐specific secondary antibody conjugated to
horseradish peroxidase and treated with a chemiluminescent
detection reagent. Proteins were visualised by development of
films which had been exposed to the membrane. TK6 cell line
expresses IRF4 protein, in contrast to the myeloid HL60 and NB4

















Figure 3.3 A goat polyclonal IRF4 antibody (Santa Cruz, M17, sc‐6059)
was used in an immunoprecipitation (IP) experiment in TK6 cells, to
assess its suitability for ChIP
A whole cell lysate prepared from TK6 cells in exponential growth
phase, was incubated with protein‐G‐sepharose (PGS) beads in a pre‐
clear step to remove non‐specifically binding proteins. The PGS beads
were then removed by centrifugation, and the lysate was incubated
with equal concentrations of either IRF4 antibody (Santa Cruz, M17, sc‐
6059) or a species‐matched control antibody. Further PGS beads were
added in order to bind the antibody‐protein complexes, and the
remaining lysate comprising unbound proteins, was removed by
centrifugation. The immunoprecipitated proteins were then separated
from the PGS bead‐antibody‐protein complexes in a denaturation step
and western immunoblotting was performed to detect IRF4 protein. A
rabbit‐derived IRF4 antibody was used to probe the membrane in the
western immunoblot. Using IRF4 antibodies raised in different species
(goat and rabbit for the IP and the western immunoblot respectively)
avoids interactions between the heavy chains of the two antibodies.
This western immunoblot demonstrated a successful
immunoprecipitation of IRF4 protein from the whole cell lysate by the
goat IRF4 antibody (lane 3), in contrast with the species‐matched
control antibody which failed to enrich the lysate for IRF4 (lane 2). The
input sample (lane 1) represents whole cell lysate that has not
undergone any immunoprecipitation and thus expresses IRF4 protein,


























Table 3.2 CD38 5’UTR and upstream flanking sequence primer sets
Primer sets 1‐4 each amplify one of the four putative IRF4 binding sequences within the
CD38 upstream flanking sequence. Primer set 5 generates an amplicon which includes








Primer set #1 ‐3.3 0.98 100.9
Primer set #2 ‐2.9 0.99 121.2
Primer set #3 ‐2.9 0.99 121.2
Primer set #4 ‐3.3 0.98 100.9
Primer set #5 ‐3.5 0.99 93.1
Table 3.3 Efficiency of CD38 primer sets 1‐5
Using a standard curve with a 2 log dilution, the efficiency of the CD38
primer sets 1‐5 was determined. The slope of the standard curve is an
indicator of the amplification efficiency, where a slope value of ‐3.32
indicates 100% efficiency. The R2 value is the coefficient of
determination. All 5 primer pairs had an efficiency of at least 93%,


















































Table 3.4 Chromatin used in initial ChIP experiments in TK6
A. To establish the experimental protocol, ChIP experiments were carried
out in TK6 cells using histone 3 (H3) antibody as a positive control. Sufficient
chromatin was obtained to use 125µg in each ChIP.
B. ChIP was then performed in TK6 using IRF4 antibody. 150µg chromatin
was used in each ChIP, but the antibody was reduced from 2µg to 1µg in the
















TK6 #3 1036 20 150 IRF4 and IgG control (2µg)







Figure 3.4 Chromatin fragments obtained from TK6 cells for
ChIP using antibody to histone 3 (H3)
Denatured samples of sheared chromatin were
electrophoresed on a 1.5% agarose gel to determine the size of
the fragments after sonication. The marker lane indicates the
size of the corresponding DNA fragments, in base pairs.
After 10 or 20 cycles of sonication, a signal is detected. While
the signal is blurred, without a discrete band, the most
concentrated signal is detected well below the marker
indicating 500bp. Chromatin fragment size of 100‐1000bp is








































Figure 3.5 Successful establishment of manual ChIP protocol in
TK6 cells, using antibody to histone 3 (H3)
ChIP was performed in chromatin prepared from exponentially
growing TK6 cells, using histone (H3) antibody as a positive
control, in order to confirm successful chromatin preparation and
manual ChIP technique.
Primer sets to the four putative IRF4 binding sites in the upstream
flanking sequence (sites 1‐4) and to the two putative binding sites
in the 5’UTR (site 5) were used to amplify DNA fragments purified
from the ChIP experiment.
There was clear enrichment of the chromatin using the H3
antibody, compared to that obtained with the species‐matched
IgG control antibody.
125µg chromatin and 2µg histone (H3) antibody (or control IgG
antibody) was used in each ChIP. Data shows the mean values
from two replicate experiments, except for site 5 where only one
experiment was performed (see section 3..3.1c). Error bars




































































































Figure 3.6 Chromatin fragments obtained from TK6 cells for ChIP using IRF4 antibody
Denatured samples of sheared chromatin were electrophoresed on a 1.5% agarose gel to determine the size of the
fragments after sonication. The marker lane indicates the size of the corresponding DNA fragments, in base pairs.
Chromatin fragments of less than 500bp were obtained after 10 and 20 cycles. Chromatin that had undergone 20 cycles




































































































Figure 3.7 ChIP using antibody to IRF4 in TK6 cells
In two independent experiments, ChIP was performed in TK6 cells using IRF4 antibody and a species‐matched control IgG
antibody. Consistent IRF4‐CD38 binding was not demonstrated at any of the 6 putative binding sites in CD38 in TK6. 150µg
chromatin was used for each ChIP.
A. Enrichment with the IRF4 antibody was not seen at any of the 5 putative IRF4 binding sites in CD38 in the first
experiment. 2µg IRF4 and species‐matched control antibody was used. Notably, binding by the IRF4 antibody appeared to
be less than that of the control IgG antibody at each of the 5 sites, suggesting excessive non‐specific binding by the IgG
antibody.
B. In order to reduce non‐specific binding with the control antibody, only 1µg of either IRF4 or control antibody was used in
the duplicate experiment. No enrichment was seen with the IRF4 antibody at sites 1‐4. Approximately two fold enrichment
was seen at site 5 in the experiment.
A B
107
Figure 3.8 Dissociation curves for CD38 primer set 5
Inspection of the dissociation curves obtained with CD38 primer set 5 in two separate experiments demonstrated
peaks in addition to the main amplicon. In addition, this primer set demonstrated the poorest amplification


































































































































Figure 3.10 Western immunoblots demonstrating the expression of IRF4
and its common binding partners in a panel of cell lines
Whole cell extracts from the cell lines indicated were used for western
immunoblotting to investigate the expression of IRF4 and its common
binding partners.
A. TK6 cell line does not express PU.1 protein (37kDa), in contrast to
MEC‐1 and its sister cell line, MEC‐2, and B lymphoma cell line, SU‐DHL‐6.
(SU‐DHL‐4 and OCI‐LY‐3 are lymphoma cell lines; HL‐60 and NB4 are
myeloid leukaemia cell lines.)
B. SU‐DHL‐6, MEC‐1 and MEC‐2 also express IRF4 protein.
C. MEC‐1 and SU‐DHL‐6 cell lines express IRF8 protein (52kDa). Neither










































5’ AGGTCAAGGGAAATTACTG                                                                    CAGAAAATTGAAACTGGAT                  AACAAAAGCGAAAATGACA                                  CA 
CAGGAACAGAAAACCAAGCAT                          CTGAGGCAAGGGGTTGGGGGTGGGAAGGGAAACAGAGAAAAGGCAAGTGAAACAGAAGGGGAGGTGCAGTTTCAGAACCC         




Two of  the previously  identified putative  IRF4  consensus binding  sites  (represented by 5’‐AANNGAAA‐3’) at base pair positions 
‐1419 and ‐128, also represent composite Ets/IRF consensus elements (EICE). These are highlighted in bright green   
The  forward  strand  sequence  is displayed  and base positions  are  indicated underneath  the  sequence. Black  text  indicates  the 
upstream flanking sequence; green text indicates 5’UTR; red text indicates coding sequence. The 5’ base position of each putative 



























































































Figure 3.12 Comparison of IRF4, PU1 and CD38mRNA expression by cell lines
A. Data from the Cancer Biomedical Informatics Grid (CaBIG) were used to investigate the levels of IRF4 and PU.1 mRNA transcript in hundreds
of cell lines. Each data point represents a cell line. Data points that indicated high expression of both IRF4 and PU.1 (marked in red) were used to
identify the corresponding cell lines.
B. CD38 mRNA transcript levels in the same cell lines were then plotted. The distribution of CD38 mRNA expression amongst the cells which
have high expression of IRF4 and PU.1 (marked in red) can be seen.
Data points corresponding to data from SU‐DHL‐6 cell line are circled in green.























































Figure 3.13 IRF4, PU.1 and CD38 mRNA expression by MEC‐1 cell line
A.MEC‐1 (indicated by blue data points) expresses IRF4 mRNA transcript and appeared to express some PU.1, though
expression of PU.1 is less than in SU‐DHL‐6 (red data points).
B. MEC‐1 also appears to weakly express CD38 mRNA transcript. However, its CD38 expression is again substantially







Figure 3.14 Flow cytometry histogram plots: CD38 expression in TK6, SU‐DHL‐6
and MEC‐1 cell lines
Cells were incubated with a PE‐conjugated isotype‐matched control antibody, or
a PE conjugated CD38 antibody. A viable cell population was gated by forward
and side scatter and this population was then analysed by a histogram plot
(shown here), in which all of the cells were captured within an M1 marker bar.
An M2 marker bar was positioned for each of the cell lines to include 5% of cells
labelled by the isotype control antibody (panels on the left). Cells labelled by the
CD38 antibody which fell within the pre‐set M2 marker bar were deemed CD38
positive (panels on the right) and expressed as % positive.
A. TK6 cells B. SU‐DHL‐6 cells C. MEC‐1 cells
Table 3.5 CD38 expression in TK6, SU‐DHL‐6 and MEC‐1 cell lines
Using the histogram plots (Figure 3.13): the percentage of CD38 positive cells
(CD38 % positivity) for each cell line was determined from the percentage of
cells falling within the pre‐set M2 marker bar after incubation with PE‐
conjugated CD38 antibody. The geometric mean fluorescence of cells labelled
with either isotype or CD38 antibody was obtained from the histogram plots,
and used to calculate the relative mean fluorescence (RMF) of the cells labelled
with CD38 antibody. It is notable that both the histogram plots (Figure 3.1.3)
and the numerical data indicate that SU‐DHL‐6 cells strongly express CD38. In
contrast, MEC‐1 cells display much weaker CD38 expression. Furthermore,
MEC‐1 cell CD38 labelling conforms to a skewed, non‐normal distribution













TK6 96.3 5.8 31.4 5.4 32.2
SU‐DHL6 100.0 7.2 2606.0 360.9 2641.7

























































Figure 3.15 Element 1 binding: ChIP sequencing (ChIP seq) data demonstrates
binding in CD38 by IRF4, PU.1 and SPI‐B in OCI‐LY3 and OCI‐LY10 lymphoma cell lines
A. The dotted red box indicates a binding peak detected by ChIP seq in the first intron
of CD38, in OCI‐LY3 and OCI‐LY10 lymphoma cell lines. IRF4 and its binding partners,
PU.1 and SPIB bind specifically between base positions 15 786 698 and 15 786 876,
and this region is designated element 1. IRF4 binding peaks are shown in green; PU.1
binding peaks are shown in brown; SPIB binding peaks are shown in blue. (With thanks
to Dr R.M.Tooze, unpublished data.)
B. The element 1 binding site and the surrounding sequence (corresponding to the
dotted red box in (A), base positions 15 786 449 to 15 787 099) are shown. A 5’‐
GGAAGTGAAA‐3’ EICE binding site is highlighted in red. ETS binding sites, 5’‐GGAA‐3’,



























Figure 3.16 Element 2 binding: ChIP sequencing data demonstrates binding in
CD38 by IRF4, PU.1 and SPI‐B in OCI‐LY3 and OCI‐LY10 lymphoma cell lines
A. The dotted red box indicates a second binding peak detected by ChIP seq at a
region in the first intron of CD38, designated element 2. Binding by IRF4, PU.1 and
SPI‐B occurs between base positions 15 807 819 and 15 808 048. IRF4 binding
peaks are shown in green; PU.1 binding peaks are shown in brown; SPIB binding
peaks are shown in blue. (With thanks to Dr R.M.Tooze, unpublished data.)
B. The element 2 binding site and the surrounding sequence (corresponding to the
dotted red box in (A), base positions 15 807 559 to 15 808 338 ) are shown. The 5’‐
TTTCTGTT‐3’ sequence (highlighted in red) indicates the presence of an IRF4

















Figure 3.17 CD38 gene and potential IRF4 binding sites
A diagrammatic representation of CD38 gene: the upstream flanking sequence, 5’UTR, first exon and intron. IRF4
binding sites (5’‐AANNGAAA‐3’) (represented by a red box) are seen in the upstream flanking sequence, 5’UTR and
intron 1. Three of these fuse the IRF4 binding site with an ETS binding site, creating the composite EICE binding
sequence (5’‐GGAANNGAAA‐3’) (represented by a green and red box). The base positions of the first nucleotide within
CD38 of each of these binding sites is indicated. The element 1 and element 2 binding sites demonstrated by ChIP
sequencing data in OCI‐LY3 and OCI‐LY10 lymphoma cell lines (section 3.3.3), are indicated.
Exon 2Intron 15’UTRUpstream flanking 
sequence

































































Primer set 5A Forward: GTGTAACCAGCCACGGAACTReverse: GGGTTCTGAAACTGCACCTC 60
Primer set 5B Forward: GTGTAACCAGCCACGGAACTReverse: GAAACTGCACCTCCCCTTCT 53
Primer set 5C Forward: ACTCTGAGGCAAGGGGTTGReverse: GGGTTCTGAAACTGCACCTC 60
Table 3.6 Primer sets to putative IRF4 binding sites in CD38 element 1 and
element 2
A. CD38 Intron 1: primer sets were designed to target the EICE site in
element 1 and the inverted IRF4 site in element 2.
B. Given that previously designed primer sets to the putative IRF4 and EICE
binding sites in the 5’UTR generated a non‐specific amplicon and had an
amplification efficiency of only 93% (section 3.3.1.d), new primer sets were




Table 3.7 Efficiency of primer sets to elements 1 and 2 in CD38 intron 1
Using a standard curve with a 2 log dilution, the amplification efficiency
and the coefficient of determination of each of the primer sets was
determined. The dissociation curves were also viewed to ensure only one
product of amplification was obtained (not shown). One primer set to
each element was then selected (boxed in red) and designated ‘element 1






Element 1 primer set 1 ‐3.15 0.98 107.7
Element 1 primer set 2 ‐3.25 0.96 103.1
Element 1 primer set 3 ‐3.05 0.96 112.8
Element 2 primer set 1 ‐3.40 0.99 96.8
Element 2 primer set 2 ‐3.45 0.97 94.9
Element 2 primer set 3 ‐3.29 1.00 101.4







Primer set 5A ‐3.3 0.99 100.9
Primer set 5B ‐3.1 0.96 110.2
Primer set 5C ‐3.2 0.95 105.4
Table 3.8 Efficiency of new primer sets to CD38 5’UTR
Using a standard curve with a 2 log dilution, the amplification
efficiency and the coefficient of determination of each of the primer
sets was determined. The dissociation curves were also viewed to
ensure only one product of amplification was obtained (not shown).

























































































































































Figure 3.18 SU‐DHL‐6 and MEC‐1 chromatin fragment size after sonication
Chromatin fragments were denatured and then electrophoresed on a 1% agarose gel. Representative gels are shown. Marker band sizes are indicated, in
base pairs.
A. SU‐DHL‐6: A discrete signal is seen after 10 and 20 cycles of sonication. Chromatin which had undergone 20 cycles of sonication was used in the first
experiment. In the subsequent two replicate experiments, SU‐DHL‐6 chromatin underwent only 10 cycles of sonication.


















































TK6 #1 727.4 10 50 IRF4 and IgG control (2µg)
TK6 #2 1079.6 10 50 IRF4 and IgG control (2µg)
TK6 #3 846.6 10 50 IRF4 and IgG control (2µg)
Table 3.9 Chromatin used for ChIP in SU‐DHL‐6, MEC‐1 and TK6 cells,
with IRF4 antibody
Chromatin was prepared for ChIP from SU‐DHL‐6 (A), MEC‐1 (B) and
TK6 (C) cells in exponential growth phase. After sonication, the
concentration of chromatin generated was determined by nanodrop.
The number of cycles of sonication used in each case is indicated. 50µg
chromatin was used for ChIP in all cases except for one MEC‐1 cell line









































Figure 3.19 ChIP in SU‐DHL‐6 using IRF4 antibody to determine
IRF4‐CD38 binding
Chromatin was manually prepared to the sonication stage from
exponentially growing SU‐DHL‐6. ChIP was then performed using the
Diagenode ChIP robot, with either 2µg of goat IRF4 antibody or 2µg
of species‐matched control antibody. The product of the ChIP then
underwent PCR amplification using the three optimised primer sets,
targeted to putative binding sites in CD38 at elements 1 and 2 (in
intron 1) and the 5’UTR. Enrichment at these sites by ChIP with IRF4
or control IgG antibody was calculated according to the input sample
(chromatin that did not undergo ChIP). Fold enrichment of the
chromatin by the IRF4 antibody was then normalised to enrichment
by the IgG control antibody. The experiment was performed in
triplicate and error bars indicate the standard error of the mean.
Asterisks indicate significant two‐tailed p values, calculated using a
two sample t‐Test. Significant binding was seen at element 1
































Figure 3.20 ChIP in MEC‐1 using IRF4 antibody to determine IRF4‐
CD38 binding
Manually prepared chromatin underwent ChIP with either 2µg of
IRF4 antibody or 2µg of species‐matched control antibody, using
the Diagenode ChIP robot. The product of the ChIP was amplified
by PCR reaction, using the three optimised primer sets, designed
to target CD38 element 1 and element 2 sites in intron 1, and the
putative binding sites in the 5’UTR. The experiment was
performed in triplicate and error bars indicate the standard error
of the mean. While the data appears to demonstrate binding at
the element 1 site, this did not reach statistical significance, using
a two sample t‐Test (p=0.090). Binding at the 5’UTR site however

































Figure 3.21 ChIP in TK6 using IRF4 antibody to determine IRF4‐
CD38 binding
Chromatin was manually prepared to the sonication stage, before
undergoing ChIP with either 2µg of IRF4 antibody or 2µg of
species‐matched control antibody, using the Diagenode ChIP
robot. The product of the ChIP was amplified in a PCR reaction
using optimised primers designed to target elements 1 and 2 in
CD38 intron 1, and a sequence in the CD38 5’UTR. The
experiment was performed in triplicate and error bars indicate
the standard error of the mean. No statistically significant binding
was demonstrated at any of the three sites, using a two sample t‐
Test. Although there was the suggestion of binding at the 5’UTR



































































































































































































































































































































Target gene Effect on target gene Binding partner Reference
3’ enhancer element of the immunoglobulin kappa 






enhancer (EλB) Activation PU.1 (Eisenbeis et al., 1995)
B domain of the immunoglobulin lambda light chain 
enhancer (EλB) Activation PU.1 or SPI‐B (Su et al., 1996)









ISG15 (an interferon‐inducible gene) Repression Alone, or with IRF8 (Rosenbauer et al., 1999)
BCL6 Repression No binding partner identified (Saito et al., 2007)
Table 4.1 IRF4 acts as a dichotomous regulator of target genes


























































Figure 4.1 Protein knockdown by RNA interference (RNAi) using short interfering (siRNA) and short hairpin (shRNA) constructs
Targeted siRNA or shRNA constructs can be used to target specific mRNA sequences for degradation, leading to reduced protein expression. Double stranded siRNA constructs are
transfected into the cell by electroporation. After unwinding, single strand target siRNA construct then combines with ribonucleoprotein in the activated multiprotein RNA‐induced
silencing complex (RISC). This complex recognises the target mRNA sequence, and the RISC Argonaute protein cleaves the mRNA. shRNA enters the cell packaged within a plasmid
vector, in lentiviral particles. The shRNA is incorporated and transcribed within the cell’s genome, and thus is passed down to daughter cells producing constitutive protein














































































































































































































































































Figure 4.2 IRF4 protein knockdown in TK6 using Combination siRNA
A. After a single electroporation with Combination siRNA targeting the IRF4 transcript, cells were collected at 24 and 48 hours (T24 and T48), and
the whole cell extracts were analysed by western immunoblotting. Knockdown of IRF4 protein was apparent at both time points, in contrast to
the two control samples which underwent electroporation only, or electroporation with an off target siRNA. Nearly 75% IRF4 knockdown was
achieved at T24, as demonstrated by densitometry. By T48, IRF4 expression was beginning to return to normal levels (65% knockdown by
densitometry).
B. In a separate experiment, cells underwent two electroporations, 24 hours apart, to see if a more durable knockdown could be achieved. 24
hours after the first electroporation, a sample of cells were collected for analysis by western immunoblotting (T24). Consistent with the first
experiment, these demonstrated 75% knockdown. The remaining cells were subjected to a second electroporation, and then collected for
analysis 24 and 48 hours later (T48 and T72 time points). Despite this double electroporation, IRF4 protein expression was returning to original























Figure 4.3 Comparing IRF4 knockdown achieved in TK6 cells using 500nM or 1µM concentration Combination siRNA
In order to ensure that the best possible IRF4 protein knockdown was being achieved, transfection with the standard concentration (500nM)
of siRNA was compared with the knockdown achieved after transfection with double this concentration (1µM). IRF4 protein expression was
determined at 24 and 48 hours post‐electroporation and quantified by densitometry. At T24, knockdown of 74% and 61% was achieved with
500nM and 1µM siRNA concentrations respectively. At T48, knockdown was 91% and 87% with the two siRNA concentrations. Standard























































































































































































































Electroporation only Off target siRNA IRF4 siRNA
T24
T48
Figure 4.4 CD38 expression in TK6 cells with transient siRNA‐mediated IRF4 knockdown
TK6 cells which had been subjected to electroporation only, transfection with an off target control siRNA, or
transfection with Combination siRNA targeted against IRF4 transcript, were analysed by flow cytometry to investigate
CD38 surface expression. Cells were incubated with a PE‐conjugated CD38 antibody, and the percentage of CD38
positive cells (captured in the M2 marker bar) and the relative mean fluorescence (RMF) of the cells (determined in
cells captured in the M1 marker bar) were determined in comparison to isotype‐labelled cells (isotype‐labelled cell
data is not shown). Flow cytometry was performed 6 hours (data not shown), 24 hours (T24) and 48 hours (T48) after a
single electroporation. These data did not indicate an effect of siRNA‐mediated IRF4 knockdown on CD38 expression























only 98 46.2 8.6
Off target siRNA 99 46.9 11.2
IRF4 99 47.8 9.6
T24
Electroporation 
only 94 25.4 7.8
Off target siRNA 98 28.4 7.7
IRF4 99 26.6 8.9
T48
Electroporation 
only 97 23.9 7.0
Off target siRNA 95 23.4 5.8
IRF4 90 18.8 4.9
Table 4.2 Flow cytometry histogram statistics demonstrating CD38 expression
in TK6 cells with transient siRNA‐mediated IRF4 knockdown
TK6 cells which had been subjected to electroporation only, transfection with an
off target control siRNA, or transfection with Combination siRNA targeted against
IRF4 transcript, were analysed by flow cytometry to investigate CD38 surface
expression. Statistics gleaned from the flow cytometry histogram plots of TK6
cells labelled with PE conjugated CD38 antibody (Figure 4.4) are demonstrated,
and indicate the percentage CD38 positivity, geometric mean fluorescence and
relative mean fluorescence (RMF) of cells. At three time points after transfection,
no substantial differences were seen between the CD38 status of cells with
siRNA‐mediated IRF4 knockdown, compared to those subjected to



























































































































T24 T48 T72 T96
IRF4
Tubulin
Figure 4.5 IRF4 protein knockdown in MEC‐1 using IRF4 Combination siRNA
In 4 independent experiments, MEC‐1 cells were transfected with IRF4
Combination siRNA, off target control siRNA, or they underwent
electroporation alone. Two representative experiments are shown, indicating
the range of knockdown achieved across the 4 replicates.
A. In this example, densitometry demonstrated IRF4 knockdown of 51%, 92%
and 98% at T24, T48 and T72 respectively.
B. In this replicate, densitometry similarly demonstrated 54% knockdown at
T24. However, less substantial knockdown was achieved at later time points
than in the experiment demonstrated in A. At T48, knockdown of only 51%



















Electroporation only Off target siRNA IRF4 siRNA
T24
T48
Figure 4.6 CD38 expression in MEC‐1 cells with siRNA‐mediated transient IRF4 knockdown
MEC‐1 cells which had been subjected to electroporation only, transfection with an off target control siRNA, or transfection with
Combination siRNA targeted against IRF4 transcript, were analysed by flow cytometry to investigate CD38 surface expression. Cells
were incubated with a PE‐conjugated CD38 antibody, and the percentage of CD38 positive cells and fluorescence of the cells was
determined in comparison to isotype‐labelled cells (isotype‐labelled cell data is not shown). Cells were analysed at 24 or 48 hours
(T24 and T48) post‐transfection. This experiment was performed using cells from two independent siRNA replicate experiments, and
representative data from one of these experiments (Figure 4.5A) is shown. IRF4 knockdown of 51% and 92% at T24 and T48 had been
achieved in the MEC‐1 cells, in this experiment (determined by western immunoblotting and densitometry). Histogram plots
demonstrated that siRNA‐mediated IRF4 knockdown had no effect on CD38 expression at 24 or 48 hours after electroporation.
Notably, however, a non‐normal distribution is observed in the CD38‐labelled MEC‐1 cells and the median fluorescence intensity is












Table 4.3 Flow cytometry histogram statistics demonstrating CD38 expression in
MEC‐1 cells with transient siRNA‐mediated IRF4 knockdown
MEC‐1 cells which had been subjected to electroporation only, transfection with an
off target control siRNA, or transfection with Combination siRNA targeted against
IRF4 transcript, were analysed by flow cytometry to investigate CD38 surface
expression. Statistics gleaned from histogram plots of MEC‐1 cells labelled with PE
conjugated CD38 antibody (Figure 4.6) are demonstrated, and indicate the
percentage CD38 positivity, geometric mean fluorescence and relative mean
fluorescence (RMF) intensity of cells. No significant differences were observed in
terms of percentage of CD38 positive cells or relative mean fluorescence of cells with
IRF4 knockdown, compared to the two control cell populations, at either time point.
Given the non‐normal distribution of the MEC‐1 cells labelled with CD38 antibody,
the median fluorescence intensity is indicated alongside the mean and relative mean
fluorescence data.












only 53.51 15.58 2.31 11.97
Off target siRNA 51.42 15.10 2.28 11.34
IRF4 49.53 15.28 2.08 11.55
T48
Electroporation 
only 43.26 13.10 1.88 10.09
Off target siRNA 39.02 13.51 1.73 10.55












































































































Figure 4.7 Transient siRNA‐mediated IRF4 knockdown in SU‐DHL‐6 cells
SU‐DHL‐6 cells transfected with Combination siRNA targeted against IRF4, an off
target control siRNA, or subjected to electroporation only, were collected at the
indicated time points after electroporation and analysed by western
immunoblotting. Four independent replicate experiments were performed, and
two representative replicates are shown.
A. Knockdown was apparent at T24 and modest knockdown remained at T48.
Densitometry was used to quantify this, and 53% and 44% knockdown was
observed at these time points respectively.
B. In a separate experiment, cells were collected at the earlier time point of 6
hours (T6) to see if any knockdown was apparent at this point. Densitometry
confirmed that knockdown was not achieved at this earlier time point. There was














Figure 4.8 CD38 expression in SU‐DHL‐6 cells with transient siRNA‐mediated IRF4 knockdown
SU‐DHL‐6 cells which had been subjected to electroporation only, transfection with an off target control siRNA, or
transfection with Combination siRNA targeted against IRF4 transcript, were analysed by flow cytometry to investigate
CD38 surface expression. Cells were incubated with a PE‐conjugated CD38 antibody, and the percentage of CD38
positive cells and relative mean fluorescence (RMF) of the cells were determined in comparison to isotype‐labelled
cells (isotype‐labelled cell data is not shown). Flow cytometry was performed 24 hours (T24) and 48 hours (T48) after
electroporation, at which time points, 42% and 68% IRF4 knockdown had been achieved, respectively (determined by
western immunoblotting and densitometry). While there is no change in the CD38 percentage positivity of the SU‐
DHL‐6 cells after siRNA‐mediated IRF4 knockdown, there is the suggestion of a downregulation of CD38 expression.
This was evidenced by a modest reduction in the relative mean fluorescence of CD38 positivity in cells with IRF4
knockdown at both time points.
T24
T48























only 99.92 2139.8 244.50
Off target siRNA 99.96 2086.38 255.55
IRF4 99.98 2074.16 175.34
T48
Electroporation 
only 99.92 2552.30 378.10
Off target siRNA 99.92 2710.95 391.49
IRF4 99.96 2521.11 322.27
Table 4.4 Flow cytometry histogram statistics demonstrating CD38 expression
in SU‐DHL‐6 cells with transient siRNA‐mediated IRF4 knockdown
SU‐DHL‐6 cells which had been subjected to electroporation only, transfection
with an off target control siRNA, or transfection with Combination siRNA targeted
against IRF4 transcript, were analysed by flow cytometry to investigate CD38
surface expression. Statistics gleaned from histogram plots of these cells labelled
with PE conjugated CD38 antibody (Figure 4.8) are demonstrated, and indicate
the percentage CD38 positivity, geometric mean fluorescence and relative mean
fluorescence (RMF) intensity of cells. There was no effect on the percentage
CD38 positivity of cells with IRF4 knockdown, and the geometric mean
fluorescence detected remained unchanged. However, there was evidence of a
modest reduction in the CD38 relative mean fluorescence detected in SU‐DHL‐6
cells with siRNA‐mediated IRF4 knockdown in comparison to cells transfected
with an off target siRNA or exposed to electroporation only. This was more
apparent at T24, but at T48 the effect was less apparent. At these two time points,
































Figure 4.9 TK6 cell populations generated after transduction with shRNA constructs targeted against IRF4
TK6 cells were transduced with six different lentivirally‐packaged shRNA constructs targeted against IRF4 transcript
(constructs 1‐6), or with two control shRNA constructs (an off target shRNA construct and an empty vector) at an
MOI (multiplicity of infection) of 2. There was modest evidence of knockdown demonstrated by western





















































































































































































Figure 4.10 TK6 cells cloned from cell populations transduced with off target shRNA or
shRNA construct 6, targeted to IRF4
Cell clones were generated on soft agar, from TK6 cell populations transduced with
shRNA construct 6, or with off target control shRNA construct. Cell clones were then
expanded and cells harvested in order to determine IRF4 expression by western
immunoblotting.
A. Four off target control clones all express IRF4 protein strongly. However, all but 1 of
the 6 cell clones produced from cells transduced with shRNA construct 6, show evidence
of substantial IRF4 protein knockdown.
B. In a replicate experiment, TK6 cells were transduced with construct 6 shRNA or off
target control construct, and cell clones were then generated. On this occasion, 9 cell
clones with shRNA‐induced IRF4 knockdown were generated. IRF4 expression is lowest
in construct 6 clones 3,4,6,7 and 9, quantified by densitometry.



















































OT clone 1 97.8 62.2 7.6
OT clone 2 94.2 42.5 5.4
OT clone 3 99.1 80.5 10.8
All OT clones 97 (±2.07) 61.7 (±15.52) 7.8 (±2.22)
Construct 6 clone 1 94.3 56.8 6.1
Construct 6 clone 2 90.9 84.8 4.6
Construct 6 clone 3 97.6 37.8 10.9
Construct 6 clone 4 94.8 54.9 6.5
Construct 6 clone 5 97.8 67.7 8.1
Construct 6 clone 6 96.5 48.1 6.8
Construct 6 clone 7 92.3 84.8 5.3
Construct 6 clone 8 97.3 35.3 8.3
Construct 6 clone 9 94.4 49.3 6.0
All construct 6 clones 95.1 (±2.29) 57.7 (±17.12) 7.0 (±1.79)
Table 4.5 Flow cytometry histogram statistics demonstrating CD38 expression in
TK6 cells with shRNA‐induced constitutive IRF4 knockdown
Cell clones derived from cell populations transduced with an off target control
shRNA or construct 6 shRNA targeting IRF4 transcript were analysed by flow
cytometry for CD38 surface expression. More than 90% of the cells from all of
the clones were positive for CD38. The mean CD38 positivity was 97.0% in the off‐
target cell clones, and 95.1% in the IRF4 knockdown clones, and this very modest
difference was not statistically significant (p=0.16, student t‐test assuming
unequal variance). No significant difference in the geometric mean fluorescence
intensity (GMF) or the relative mean fluorescence (RMF), was seen in any of the
construct 6 clones with IRF4 knockdown, compared to the off target control
clones. The relative mean fluorescence of the IRF4 knockdown clones was 7.0, in





























































































































































































































































Figure 4.11 ChIP using IRF4 and H3K4me3 antibodies in MEC‐1 cells with siRNA‐mediated IRF4 knockdown
MEC‐1 cells were transfected with either Combination siRNA targeted against IRF4, or off target control siRNA. Cells were harvested 24 hours (A and
B) or 48 hours (C and D) after transfection, and used in ChIP experiments.
A. 24 hours after electroporation, cells transfected with control siRNA demonstrated IRF4‐CD38 binding at the element 1 and 5’UTR binding sites.
Less binding occurred at all three sites in cells with transient siRNA‐mediated IRF4 knockdown.
B. In the same cells, binding of H3K4me3 at all three sites was negligible in the off target control cells. However, notably, binding at the 5’UTR site
was significantly increased in cells with siRNA‐mediated IRF4 knockdown. H3K4me3 is associated with transcriptional gene activation.
C. 48 hours after electroporation, evidence of IRF4‐CD38 binding was reduced at element 1 binding site in the MEC‐1 cells with IRF4 knockdown.
Technical issues rendered binding at the 5’UTR site uninterpretable in this experiment.
























































































































































Figure 4.12 ChIP using IRF4 and H3K9me3 antibodies in SU‐DHL‐6 cells with siRNA‐
mediated IRF4 knockdown
SU‐DHL‐6 cells were transfected with either Combination siRNA targeted against
IRF4, or off target control siRNA. Cells were harvested 24 hours after transfection,
and used in ChIP experiments.
A. Cells transfected with off target control siRNA demonstrated IRF4‐CD38 binding
at the element 1 binding site. This was substantially reduced in cells with siRNA‐
mediated IRF4 knockdown. Data from the 5’UTR site failed due to technical issues.
B. In the same cells, binding at the element 1 site by H3K9me3 was seen in cells
transfected both with off target control siRNA or Combination siRNA targeted
against IRF4. However, H3K9me3 binding was substantially greater in cells with





























































































































































































































































































































































Figure 5.1 Proliferation of MEC‐1 cells with transient siRNA‐mediated
IRF4 knockdown
MEC‐1 cells were transfected with Combination siRNA targeted against
IRF4, an off target control siRNA, or subjected to electroporation only.
Analysis by western immunoblotting and densitometry demonstrated
knockdown of at least 50%, 24 hours after electroporation, and the
cells were plated at this point. Cells were seeded at 5x104/ml in sterile
6 well culture plates, and counted at 24 hour intervals for 5 days. The
experiment was repeated in duplicate using cells from two
independent siRNA experiments, and IRF4 knockdown of over 90% was
achieved in the cells from one of these experiments. Knockdown of
IRF4 protein did not affect the proliferation of MEC‐1 cells. Error bars




















































Figure 5.2 Effect of DMSO on siRNA treated MEC‐1 cells
In order to determine the cytotoxic effect of DMSO which was used as a
diluent for ibrutinib and fludarabine in growth inhibition studies, MEC‐1 cells
were exposed to DMSO alone, at the highest concentration of DMSO used in
the drug‐treated wells. MEC‐1 cells which had been subjected to
electroporation only, transfection with an off target siRNA or transfection with
Combination siRNA targeted against IRF4, were seeded at 5x104/ml in sterile 6
well culture plates, and exposed to DMSO at a concentration of 0.03% (A) or
0.1% (B). One representative experiment is shown in both cases.
A. There was no evidence of substantial cytotoxicity in any of the cells exposed
to 0.03% DMSO compared to the untreated cells (p = 0.34).
B. The higher concentration of DMSO (0.1%) also did not negatively impact on
cell growth (p =0.50). The cells transfected with an off target siRNA appeared
























































































































Figure 5.3 Fludarabine cytotoxicity in MEC‐1 cells with siRNA‐mediated
IRF4 knockdown
MEC‐1 cells which had been subjected to electroporation only, transfection
with an off target siRNA or transfection with Combination siRNA targeted
against IRF4, were seeded at 5x104/ml in sterile 6 well culture plates, and
treated with fludarabine. Cells were then counted in exponential growth
phase, and a percentage of surviving cells at each drug dose was calculated
in comparison to the survival of cells treated with DMSO vehicle only.
A. Cells with demonstrable IRF4 knockdown of 50‐100% were treated with
fludarabine in a dose range 0‐15µM. At all doses, there was evidence of
reduced drug‐sensitivity in the cells with IRF4 knockdown.
B. Given that 15µM fludarabine did not achieve more than 85% cell killing,
cells from two independent siRNA experiments were then treated with
fludarabine at higher doses, ranging up to 50µM. There was no evidence of
differential drug sensitivity in the IRF4 knockdown cells at these doses.
Error bars represent standard error of the mean for the two experiments.
However, the maximum IRF4 knockdown achieved with siRNA transfection
in the cells used in these experiments with higher dose fludarabine (up to


























MEC‐1 cells which had been subjected to electroporation only,
transfection with an off target siRNA or transfection with Combination
siRNA targeted against IRF4, were seeded at 5x104/ml in sterile 6 well
culture plates, 24 hours after electroporation, and treated with ibrutinib
at a dose range of 0‐50µM. Cells were counted in exponential growth
phase and normalised to growth inhibition in cells treated with DMSO
only. The experiment was repeated in duplicate, using cells from two
independent siRNA experiments with maximal IRF4 knockdown of 55‐
60%, demonstrated by western immunoblotting and densitometry.
There was no apparent effect on drug sensitivity in cells with IRF4



































Six hours after transfection with Combination siRNA targeted against
IRF4, transfection with an off target control siRNA, or electroporation
only, cells were seeded at 5x104/ml in sterile 6 well culture plates
and counted at 24 hour intervals. The experiment was repeated in
triplicate. The SU‐DHL‐6 cells with siRNA‐mediated IRF4 knockdown
grew significantly more slowly than those subjected to
electroporation only or to transfection with an off target control
siRNA (p value =0.037 and 0.032 respectively, by two way ANOVA).
Mean knockdown of nearly 70% in the three independent siRNA
experiments, was demonstrated by western immunoblotting and
densitometry, 24 hours after electroporation. Error bars represent




























































Figure 5.6 Effect of DMSO on siRNA‐treated SU‐DHL‐6 cells
In order to determine the cytotoxic effect of DMSO which was used
as a diluent for fludarabine in growth inhibition studies, SU‐DHL‐6
cells were exposed to DMSO alone, at the highest concentration of
DMSO used in the drug‐treated wells. SU‐DHL‐6 cells which had
been subjected to electroporation only, transfection with an off
target control siRNA or transfection with Combination siRNA
targeted against IRF4, were seeded at 5x104/ml in sterile 6 well
culture plates, and exposed to DMSO at a concentration of 0.1%.
The growth of these DMSO‐exposed cells was compared to
untreated cells. DMSO did not significantly affect cell growth
(p=0.07) and there was some evidence of it having a hormetic effect
in the cells transfected with siRNA, which appeared to grow more























Figure 5.7 Fludarabine cytotoxicity in SU‐DHL‐6 cells with siRNA‐
mediated IRF4 knockdown
Six hours after electroporation, SU‐DHL‐6 cells which had been
subjected to electroporation only, transfection with an off target
siRNA or transfection with Combination siRNA targeted against
IRF4 protein, were seeded at 5x104/ml in sterile culture plates and
treated with fludarabine at a dose range of 0‐50µM. The cells were
counted in exponential growth phase, and the cell counts were
normalised to cells that had simultaneously been exposed to
DMSO only. The experiment was repeated in two independent
replicates with demonstrable IRF4 knockdown of between 65 and
over 80%, 24 hours after electroporation. IRF4 knockdown had no
effect on the cells’ sensitivity to fludarabine. Error bars represent































Figure 5.8 Proliferation of TK6 cell clones with shRNA‐mediated
constitutive IRF4 knockdown
Nine cell clones were generated from TK6 cells which had been
transduced with shRNA construct 6 targeted against IRF4, and three cell
clones were generated from cells transduced with an off target control
shRNA. The IRF4 knockdown achieved in the target clones ranged from 50‐
100%. In two independent experiments (A and B), cells were seeded at
5x104/ml in sterile 6 well culture plates, and counted at 24 hour intervals.
In both cases, proliferation in cell clones with IRF4 knockdown was slowed
compared to those without IRF4 knockdown. This approached, and
reached statistical significance by two way ANOVA with p values of 0.06




































































Figure 5.9 Effect of DMSO on TK6 cells with shRNA‐mediated constitutive
IRF4 knockdown
TK6 cells with shRNA‐mediated IRF4 knockdown were treated with
fludarabine in growth inhibition assays. In order to determine any
cytotoxicity of the DMSO vehicle in which fludarabine was delivered, cells
were treated separately with DMSO alone, at the highest concentration of
DMSO achieved in the drug‐treated wells. Nine cell clones transduced with
shRNA Construct 6 targeted against IRF4, and three cell clones transduced
with an off‐target control shRNA construct, were each seeded at 5x104/ml
in sterile culture plates and treated with DMSO at 0.1% (A) or 0.15% (B).
Cells were counted in exponential growth phase, and compared to cells
untreated with DMSO. Error bars represent the standard error of the
mean. Cell growth in cells exposed to DMSO, was modestly impaired, at
both DMSO concentrations. This reached statistical significance when






































Figure 5.10 Growth inhibition with fludarabine (0‐10µM) in TK6 cell clones with shRNA‐mediated constitutive IRF4
knockdown
TK6 cell clones generated from cells transduced with an off target shRNA construct or with construct 6 shRNA targeted against
IRF4, were seeded at 5x104/ml in sterile 6 well plates and treated with fludarabine at the doses indicated. Cells were counted
in exponential growth phase, and growth was normalised to cells which had been treated with DMSO alone (the vehicle in
which fludarabine was delivered). Error bars represent the standard error of the mean.
A. No significant difference in growth inhibition was seen between three off target clones and nine clones with IRF4
knockdown, when they were treated with fludarabine doses up to 1µM. There was however, differential killing at the highest
dose of 10µM where IRF4 knockdown clones were more sensitive to the drug than the control clones (p=0.007).
B. Given the evidence of differential killing at 10µM fludarabine, the two knockdown clones with the lowest expression of IRF4
by immunoblotting and densitometry (clones 4 and 6) were compared separately to the three off target clones. There is the
suggestion of a further increase in sensitivity to fludarabine at 10µM in these two clones.
C. This effect is lost when the two knockdown clones with the highest expression of IRF4 by densitometry (clones 1 and 2) are








































































































Figure 5.11 Growth inhibition with fludarabine (0‐15µM) in TK6 cell clones with shRNA‐mediated constitutive IRF4
knockdown
Three control TK6 cell clones generated from cells transduced with an off target shRNA construct and nine TK6 cell clones
with constitutive IRF4 knockdown, generated from cells transduced with construct 6 shRNA targeted against IRF4, were
seeded at 5x104/ml in sterile 6 well plates and treated with fludarabine at the doses indicated. Cells were counted in
exponential growth phase, and growth was normalised to cells which had been treated with DMSO alone (the vehicle in
which fludarabine was delivered). Error bars represent the standard error of the mean.
A. Taken altogether, there was very little evidence in this experiment that IRF4 knockdown in the nine knockdown clones
affected TK6 cell sensitivity to fludarabine at doses up to 15µM.
B. However, when the fludarabine‐sensitivity of the lowest IRF4‐expressing knockdown clones (clones 4) was compared
directly to the three control clones, there was evidence of increased cytotoxicity in the clone with IRF4 knockdown at doses
of 10 and 15µM.

















































































































Figure 5.12 Bendamustine cytotoxicity in TK6 cells with stable shRNA‐
mediated IRF4 knockdown
TK6 cell clones with shRNA mediated IRF4 knockdown, and TK6 cell clones
generated from cells transduced with an off target shRNA construct, were
seeded at 5x104/ml in a sterile 6 well plate and treated with
bendamustine at the doses indicated. Cells were simultaneously treated
with sterile water (the vehicle in which bendamustine was delivered)
alone, and growth inhibition in bendamustine‐treated cells was
normalised to the the vehicle‐only wells. Error bars represent standard
error of the mean.
A. In an initial experiment, four knockdown clones (the two highest IRF4
expressors and the two lowest IRF4 expressors) were compared with the
three control clones. There was no evidence of an effect of IRF4
knockdown on bendamustine sensitivity.
B. The experiment was repeated using all nine knockdown clones in
comparison with the three control clones. Again, IRF4 knockdown did not

















































































Cell line/ tumour type Origin of cell Evidence for effect of IRF4 on growth Reference
SU‐DHL‐6 GC origin, mature B cell Growth impaired by IRF4 knockdown Figure 5.5
TK6  Immature pre‐GC centre, lymphoblastoid B cell Growth impaired by IRF4 knockdown Figure 5.8




Plasma cells Post GC mature B cells IRF4 does not target genes such as MYC (Shaffer et al., 2008)
Hodgkin lymphoma cell 
lines* GC B cells Growth impaired by IRF4 knockdown (Aldinucci et al., 2011)
Myeloma cell lines$ Post GC mature B cells Growth impaired by IRF4 knockdown (Shaffer et al., 2008; Yang et al., 2012)
Germinal centre 







Table 5.1 Effect of IRF4 on proliferation of a range of B cell lines
*Hodgkin lymphoma cell lines included: KM‐H2, HDLM‐2, L‐428
$Myeloma cell lines included: ANBL6, UTMC2, L363, JIM3, LP1, EJM, KMS12, OCI‐My5, SKMM1, H929
**Germinal centre lymphoma cell lines included: BJAB, OCI‐Ly19, OCI‐Ly7, Ramos, HT












































































































































1 del(11q), del(13q)CD38+ Immunoblotting: IRF4 expression
2 CD38‐ Immunoblotting: IRF4 expressionCFSE labelling
3 CD38+ Immunoblotting: IRF4 expressionChIP studies
4 CD38‐ Immunoblotting: IRF4 expressionChIP studies
5 CD38‐ Immunoblotting: IRF4 expressionChIP studies
6 CD38‐ Immunoblotting: IRF4 expressionChIP studies




9 CD38‐ Immunoblotting: IRF4 expressionChIP studies
10 CD38‐ Immunoblotting: IRF4 expression




15 Normal karyotype Upregulation of IRF4 on CD40L monolayer co‐culture
16 CD38+ Upregulation of IRF4 on CD40L monolayer co‐culture
17 CD38‐ Flow cytometry to determine CD38 expression
18 CD38+ Flow cytometry to determine CD38 expression
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Table 6.1 Patient characteristics
Blood enriched for primary CLL lymphocytes was obtained from 18 patients by separation
from whole blood by density medium gradient centrifugation. The samples were then used
in a number of investigations: western immunoblotting to determine IRF4 expression; CFSE
labelling and flow cytometry to determine evidence of proliferation after CD40L monolayer
co‐culture; flow cytometry to determine CD38 expression; ChIP studies to determine IRF4‐
CD38 binding, and binding by histone methylation marks to CD38. The experiments in which
each sample was used are indicated.
212
IRF4 52kDa
1 2 3 4 5 6 7 8 9 10 11
Patients
Figure 6.1 IRF4 expression by western immunoblotting in primary lymphocytes from 11 CLL patients
Primary CLL lymphocytes were obtained from 11 patients and whole cell extracts were prepared prior to co‐culture. After quantifying the protein
concentration obtained from each sample using Pierce BCA assay, equal quantities of protein per sample were loaded for gel electrophoresis by SDS‐PAGE.
IRF4 expression was heterogeneous. Two of the patients (patients 2 and 11) did not express IRF4. Three patients (patients 5, 9 and 10) had weak expression.
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Primary CLL cells separated from peripheral blood on a density medium gradient were cultured on a CD40L‐expressing mouse fibroblast
monolayer (CD40L), or simultaneously on a control non‐expressor fibroblast layer (NTL). CLL cells were then harvested at the time
points indicated and cellular proteins were extracted for western immunoblotting to determine the level of IRF4 protein expression.
Whole cell extract protein content was quantified by BCA assay and equal quantities of protein were loaded for each protein
electrophoresis. IRF4 expression in primary CLL lymphocytes after CD40L co‐culture was investigated in 5 patients. IRF4 expression was
consistently upregulated in all of these 5, and representative western immunoblots of cells from 4 patients are demonstrated here.
A. CLL cells from two patients, (12 and 13) both expressed IRF4 at T0 prior to co‐culture. After 24 hours on co‐culture, IRF4 expression
was substantially greater in the CLL cells that had been cultured on the CD40L‐expressing monolayer, compared to those cultured on
the control NTL monolayer.
B. Similarly, CLL cells from patient 14 expressed more IRF4 protein at time points T24 and T48 when they were cultured on CD40L
monolayer.
C. Cells from patient 15 were cultured on the CD40L or control NTL monolayer for up to 6 days. IRF4 expression continued to be greater





















































Primary CLL lymphocytes from two patients (patients 2 and 8) were labelled with
carboxyfluorescein succinimidyl ester (CFSE). The cells were then cultured on a
CD40L monolayer or on an NTL monolayer. Cells were collected at days 1, 5, 9 and 12
and analysed by flow cytometry. Representative dot plots demonstrating cell size and
complexity (A), and CD5/ CD19 positivity (B) are indicated from day 12 for all cells.
Overlay histograms demonstrating CFSE expression at days 1,5,9 and 12 (from right
to left) for all cells are shown (C). Forward and side scatter measurements indicated
an increase in the size and complexity of CLL cells cultured on the CD40L monolayer
compared to those cultured on the NTL monolayer (A). Cells from both patients
demonstrated only a modest reduction in CFSE fluorescence intensity from days 1 to
12 with a constant number of cells seen per peak, when cultured on the NTL
monolayer (C). However, cells cultured on the CD40L monolayer demonstrated a
clear reduction in CFSE intensity coupled with a reduction in the cell numbers in each








































































culture 1.01 5.73 0.78
CD40L co‐








culture 77.79 89.51 11.5
CD40L co‐
culture 70.37 81.38 7.46
Table 6.2 CD38 expression in primary CLL lymphocytes after co‐culture on CD40L
monolayer
Primary lymphocytes from two CLL patients: patient 17 (known to be CD38‐) and patient
18 (known to be CD38+) were cultured on the NTL monolayer or CD40L monolayer for 24
hours and then analysed by flow cytometry to investigate any early effect on CD38
surface expression. Prior to co‐culture, CD38 negativity was confirmed in patient 17
(4.97% CD38 positivity) and patient 18 was confirmed to be 89.83% CD38+. After 24
hours on the co‐culture monolayers, there appeared to be a modest increase in CD38%
positivity and geometric mean fluorescence in patient 17 cells that had been cultured on
the CD40L monolayer. However, the relative mean fluorescence (RMF), which also takes
into account the geometric mean fluorescence intensity of the isotype‐control labelled
cells appeared unchanged. In contrast there did appear to be a modest reduction in
CD38% positivity and geometric mean fluorescence in patient 18 cells after co‐culture on
the CD40L monolayer. This reduction was also seen in the RMF.
Figure 6.4 CD38 expression in primary CLL
lymphocytes from a CD38+ CLL patient, after co‐
culture on a CD40L monolayer
Primary CLL lymphocytes from patient 18 (CD38+)
were co‐cultured on the NTL and CD40L monolayers
for 24 hours and then analysed by flow cytometry
to investigate CD38 expression. It was noted that
the histogram plots revealed the suspicion of a
bimodal cell population in the cells that had been
co‐cultured on the CD40L monolayer. (A) Cells that
had been co‐cultured on the NTL monolayer







































Figure 6.5 IRF4‐CD38 binding in primary CLL cells: patient 6
The mononuclear cell fraction, containing CLL lymphocytes, was separated from peripheral blood of patient 6 by density medium gradient
centrifugation. After formaldehyde cross‐linking, chromatin was manually prepared from the cells by lysis and then sonicated, to produce
chromatin fragments for ChIP.
A. Chromatin fragments were electrophoresed on a 1% agarose gel to determine fragment size after 0, 5 and 10 cycles of sonication. After 10
cycles of sonication, fragments of between 100‐200 base pairs were obtained, and these were used in ChIP. Marker band sizes are indicated, in
base pairs.
B. There was very little evidence of IRF4‐CD38 binding either at the element 1 or element 2 binding sites in intron 1 of CD38, or at the 5’UTR




































































































































3 262 452 25
4 47 274 27
5 103 536 45
6 382 557 25
7 104 541 45
9 324 478 25
Table 6.3 DNA yield from chromatin fragments after sonication: a
comparison of DNA yield from primary CLL cells cultured on CD40L
monolayer with cells cultured on NTL monolayer
Primary CLL lymphocytes were harvested after co‐culture on CD40L
monolayer or NTL monolayer. After formaldehyde cross‐linking, cells were
lysed to isolate chromatin and the lysate was then sonicated to produce
chromatin fragments for ChIP. In the majority of cases (6 of 8), the DNA
yield determined by nanopdrop was substantially greater for cells collected
from the CD40L monolayer than for cells collected from the NTL




























































































Figure 6.6 Agarose gel electrophoresis of chromatin fragments obtained from primary CLL lymphocytes from 3 patients, after CD40L
monolayer co‐culture
Primary CLL lymphocytes from 3 patients: patient 7 and 5 (A) and patient 4 (B) were co‐cultured on a CD40L monolayer for three days. After
harvesting the cells, chromatin was manually prepared. Sonicated chromatin fragments were then electrophoresed on a 1% agarose gel to






































































































Figure 6.7 IRF4‐CD38 binding in primary CLL lymphocytes from 3 patients after co‐
culture on CD40L monolayer
Primary CLL lymphocytes from three patients were co‐cultured on a CD40L
monolayer for 3 days. Chromatin was then prepared from these cells, and used to
determine IRF4‐CD38 binding by ChIP, at putative IRF4 binding sites in CD38.
A. There was very little evidence of IRF4‐CD38 binding in patient 7.
B. There was some evidence of IRF4 binding in patient 5 with 7‐fold enrichment of
binding by IRF4 antibody at the element 1 EICE binding site and at the 5’UTR binding
site.
C. There was substantial evidence of IRF4‐CD38 binding in patient 4 with 45‐fold

































































































































































































Primary CLL lymphocytes from patient 3 were co‐cultured on CD40L or NTL monolayers simultaneously for 4 days. Cells were then harvested and
chromatin was manually prepared.
A. After sonication, chromatin fragments were electrophoresed on a 1% agarose gel. This demonstrated that appropriate chromatin fragments
lengths had been obtained after 10 cycles of sonication, from cells cultured in both co‐culture conditions. In addition, sufficient chromatin was
available from cells from both co‐culture conditions. ChIP was therefore performed on chromatin from both cell populations (NTL and CD40L
monolayer co‐culture), to determine evidence of IRF4‐CD38 binding. Size of marker bands is indicated in base pairs.




























































































































































































































Figure 6.9 ChIP in patient 3 investigating binding by IRF4, H3K9me3 (repressive histone mark) and H3K4me3 (activating histone mark) antibody in CD38
A.Minimal IRF4‐CD38 binding was observed after both NTL and CD40L monolayer co‐culture. Some binding by H3K9me3 repressive histone mark was apparent,
but this did not vary substantially between cells co‐cultured on NTL monolayer and those cultured on CD40L monolayer.
B. Subsequently, a ChIP using H3K4me3 activating histone mark antibody was performed. This showed a substantial downregulation in antibody binding in cells


























































Figure 6.10 ChIP using antibody to H3K9me3 (repressive histone mark) in primary CLL lymphocytes from patient 9 after co‐culture on
CD40L monolayer
A. Chromatin was prepared from cells from patient 9 after 3 days of co‐culture on CD40L monolayer. Electrophoresis of sonicated
chromatin fragments on a 1.5% agarose gel demonstrated that fragments of 100‐200 base pairs had been generated after 5 cycles of
sonication.
B. ChIP using an antibody to H3K9me3 (a histone mark indicative of transcriptional repression) demonstrated evidence of substantial
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